News >

Margetuximab Elicits Modest Survival Extension in HER2+ Breast Cancer

Gina Columbus @ginacolumbusonc
Published: Wednesday, Oct 23, 2019

breast cancer
The combination of margetuximab and chemotherapy induced a 1.8-month median overall survival (OS) increase in patients with pretreated HER2-positive metastatic breast cancer compared with trastuzumab (Herceptin) and chemotherapy, according to topline findings of a second prespecified interim OS analysis of the phase III SOPHIA trial.1

 

References

  1. MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer. Macrogenics. Published October 22, 2019. https://bit.ly/32GPSl3. Accessed October 23, 2019.
  2. Rugo HS, Im S-A, Wright GLS, et al. SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). J Clin Oncol. 2019;37(15 suppl; abstr 1000). doi: 10.1200/JCO.2019.37.15_suppl.1000.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x